Anti-Yo Associated Paraneoplastic Cerebellar Degeneration in Ovarian Cancer: A Rare Case Report
Received Date : 02 Sep 2020
Accepted Date : 03 Dec 2020
Available Online : 02 Feb 2021
Doi: 10.37047/jos.2020-78768 - Article's Language: EN
J Oncol Sci. 2021;7(1):31-3
This is an open access article under the CC BY-NC-ND license
Paraneoplastic cerebellar degeneration (PCD) is a rare neurological complication in cancer, characterized by the rapid development of cerebellar ataxia. It is mostly seen in gynecological cancers, breast cancer, and small cell lung cancer. Here, we present a case of anti-Yo-associated PCD in an ovarian cancer patient. A recurrence in ovarian cancer was observed in this patient after the diagnosis of PCD.
  1. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7: 327-340. [Crossref] 
  2. Fanous I, Dillon P. Paraneoplastic neurological complications of breast cancer. Exp Hematol Oncol. 2015;5:29. [Crossref]  [PubMed]  [PMC] 
  3. Shams'ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003;126:1409-18. [Crossref]  [PubMed] 
  4. Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain. 1997;120:1279-300. [Crossref]  [PubMed] 
  5. Croft PB, Wilkinson M. The incidence of carcinomatous neuromyopathy in patients with various types of carcinoma. Brain 1965; 88: 427-434. [Crossref]  [PubMed] 
  6. Goldstein BH, Birk CL, Van Houten M, et al. Ovarian cancer and late onset paraneoplastic cerebellar degeneration. Arch Gynecol Obstet 2009; 280: 99- 101. [Crossref]  [PubMed] 
  7. Power DG, McVey GP, Delaney DW, et al. Papillary serous carcinomas of the uterine cervix and paraneoplastic cerebellar degeneration: a report of two cases. Acta Oncol 2008; 47: 1590- 3. [Crossref]  [PubMed] 
  8. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75:1135-40. [Crossref]  [PubMed]  [PMC] 
  9. Le May M, Dent S. Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a patient with breast cancer: a case report and literature review. Curr Oncol. 2018;25(6):e585-e591. [Crossref]  [PubMed]  [PMC] 
  10. Sakai K, Shirakawa T, Li Y, et al. Interaction of a paraneoplastic cerebellar degeneration-associated neuronal protein with the nuclear helix-loop-helix leucine zipper protein MRG X. Mol Cell Neurosci 2002; 19: 477-484. [Crossref]  [PubMed] 
  11. Jarius S, Wildemann B. 'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti‐Yo/CDR2, anti‐Nb/AP3B2, PCA‐2, anti‐Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook. J Neuroinflammation 2015; 12: 168. [Crossref]  [PubMed]  [PMC] 
  12. Albert ML, Darnell JC, Bender A, et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998;4:1321-1324. [Crossref]  [PubMed] 
  13. Cao Y, Abbas J, Wu X, et al. Anti-Yo-positive paraneoplastic cerebellar degeneration associated with ovarian carcinoma: case report and review of the literature. Gynecol Oncol. 1999;75:178-183. [Crossref]  [PubMed] 
  14. de Beukelaar JW, Sillevis Smitt PA. Managing paraneoplastic neurological disorders. Oncologist 2006; 11: 292- 305. [Crossref]  [PubMed]